

18 February 2015

Suite 1, 1233 High Street  
Armadale VIC 3142

---

**Imugene Receives \$230K Research and Development Tax Refund**

---

Imugene Limited (ASX:IMU) has received a research and development tax refund of \$230,690 as part of the Australian government's R&D incentive program.

These funds complement Imugene's \$3.5 million capital raising announced in December and will contribute to the progression of the company's main asset, HER-Vaxx, due to enter additional human Phase Ib/II gastric cancer clinical trials later this year.

"Imugene's research capability is strengthened by this financial support. This clinical research on HER-Vaxx is attempting to develop much better treatments for HER-2 positive gastric and other cancers and is striving to help sufferers and benefit healthcare," said Mr Charles Walker, Managing Director of Imugene.

"Our endeavour is to achieve one or more breakthroughs in these areas with superior commercial products. This non-dilutive funding helps us move down this path. I expect Imugene to continue to benefit from this innovative R&D refund scheme in future years."

**Charles Walker**  
**Managing Director**

Tel: +61 (0) 4 5044 6990  
Cwalker[at]imugene.com  
[www.imugene.com](http://www.imugene.com)

**Paul Hopper**  
**Executive Chairman**

Tel: +1 858 334 5820 (US)  
Tel: +61 406 671 515 (Australia)  
receptogen[at]earthlink.net

**Media contact:**

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333  
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.